You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

58 Results
Guidelines and Advice
Status: Current
ID: 12-11
Version: 2
Apr 2023
Guidelines and Advice
Status: Current
ID: GL 17-10 v2
Version: 2
Mar 2025
Drug
Other Name(s): Vectibix®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Drug
Other Name(s): Votrient®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Alimta®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2023
Drug
Other Name(s): Caelyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Pomalyst®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2025
Drug
Other Name(s): Iclusig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Drug
Other Name(s): Keytruda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Ibrance™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2025
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    procarbazine
ODB - General Benefit
    lomustine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
procarbazine,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023

Pages